Breast Cancer Survivorship & Work-Related Cognitive Limitation

PURPOSE AND JUSTIFICATION

Cancer related psychological sequelae have significant impact on breast cancer survivors'
cognitive functioning. Depression and negative affect have been shown to be highly
correlated with reduced verbal knowledge, verbal memory, spatial ability, and figural
memory. In addition, self-reported psychological stress was correlated with perceived
cognitive deficits and poor performance on tests of memory, verbal fluency, and attention in
breast cancer patients post-treatment. Similarly, depression and anxiety among breast cancer
survivors have shown to be significantly correlated with subjective cognitive dysfunction
including reduced attention, concentration, and memory. Moreover, persisting somatic
sequelae including pain, fatigue, and sleep disturbances have indirect critical influence on
breast cancer survivors' cognitive functioning. The study by Caplette-Gingras, Savard,
Savard, and Ivers indicated that breast cancer survivors with sleep disturbance exhibited
reduced cognitive functioning in episodic memory and executive functioning and reported
subjective cognitive deficit in comparison to breast cancer survivors without sleep
disturbances. Further, fatigue and cognitive dysfunction have shown significant association
among breast cancer survivors. Somatic challenges that persist after the survivors'
completion of treatment clearly exhibit adverse cognitive impairment.

Cognitive deficit is one of the cognitive sequelae of breast cancer that adversely impacts
survivors' general well-being. Persisting psychological and somatic symptoms and various
treatments received for breast cancer are some reasons for cognitive deficits post-cancer.
Chemotherapy and hormonal blockade therapy have been directly associated with adverse
impacts on cognitive functioning including memory, executive functioning, and attention.
Radiotherapy and surgery have also shown to impact breast cancer survivors' cognitive
functioning. These cognitive impairments impact survivors' quality of life and general
functioning. Therefore, enduring cognitive deficits resulting from breast cancer and its
treatments have significant effect on survivors' health and re-establishment of normalcy.
While breast cancer survivorship bolsters hope for a cancer-free life, enduring
cancer-related symptoms impacts the survivors' occupational and social functioning, which in
return may impinge on their recovery. Returning to the previously held roles allows a
better recovery from breast cancer treatments, longer survivorship and lower reoccurrence
rate. However, breast cancer survivors are among the majority of about 13% of cancer
survivors that stop working 4 years post-cancer due to "cancer-related reasons". Employed
women with breast cancer history report learning, long-term memory, attention,
concentration, and executive functioning problems. Hence, these reported cognitive
difficulties impact job performance, ability to work, and job maintenance. These cognitive
deficits not only impact the breast cancer survivors' work performance and ability to retain
their position but they also impact the survivors' psychological and social well-being and
vice-versa.

Most individuals who experience psychological (i.e., depression, anxiety) and somatic
distress (pain, fatigue and sleep) have reported cognitive difficulties and shortcomings.
Similarly, breast cancer survivors report experiencing cognitive difficulties in relation to
their psychological and somatic distresses. Although, cognitive difficulties experienced by
individuals' with and without cancer history has an impact on individuals quality of life
and level of functioning; the cognitive deficit breast cancers survivors endure through
cancer treatment (i.e., chemotherapy) impacts their cognitive functioning on a greater
extend. This shortcoming post cancer treatment impacts cancer survivors' everyday
functioning and quality of life on a different level, which impacts their survivorship
experience and overall functioning.

Cognitive limitation among breast cancer survivors in the context of work assesses cognitive
deficits that survivors experience at work. Given that cognitive functioning among breast
cancer survivors is affected by various factors, such as cancer diagnosis and treatment,
work-related cognitive limitation might also be impacted by numerous variables.
Nevertheless, there are more studies yet to be done exploring work-related cognitive
limitation among employed breast cancer survivors in association with various cancer-related
symptoms. Most studies have assessed implication of survivorship and work performance
outcome among breast cancer survivors but few have focused on work-related cognitive
limitation. For example, work-output and performance have been shown to be impacted
negatively as a result of persisting symptoms experienced by breast cancer survivors, such
as fatigue and reduced physical and mental ability. The few studies that have investigated
work-related cognitive limitation have looked at the relationship between work-related
cognitive limitation and work output. Other than Ottati and Feuerstein, no other study has
looked at the relationship between cancer-related symptoms and work-related cognitive
limitations among breast cancer survivors. Although, the study by Ottati and Feuerstein has
looked at the relationship between cancer-related symptoms and work-related cognitive
limitation, they only assessed depression, anxiety, fatigue and pain as cancer-related
symptoms. They did not assess the association of cognitive functioning and sleep
disturbance as cancer-related symptoms in relation to work-related cognitive limitation. In
addition, their study did not involve a healthy control group to assess for any differences
amongst the two groups.

The proposed study seeks to evaluate the relationship between biopsychosocial functioning
and work-related cognitive limitation among employed breast cancer survivors in a
cross-sectional study with healthy control group. Specifically, this study will assess
work-related cognitive limitation in association with depression, anxiety, pain, fatigue,
sleep disturbance, and cognitive deficit of employed women with and without history of
breast cancer. The primary purpose of this study is to assess the impact of objective
cognitive functioning as a better predictor of cognitive shortcomings at work place in
comparison to a self-report cognitive measure. The secondary purpose is to assess work
related cognitive limitation in breast cancer survivors in comparison to their counterparts
(employed women without history of cancer diagnosis). The third purpose is to explore how
sociodemographic variables such as marital status, education, age, race, and ethnicity
relates to perceived cognitive limitation at work among breast cancer survivors.
Additionally, the study will examine the effects of medical variables as covariates on these
relationships. Subsequently, the study will examine the level of mindful attention and
awareness as a possible mediator between the psychological, somatic and cognitive distress
and the work-related cognitive limitation.

I. STUDY AIM AND HYPOTHESIS

1. Hypothesis or question (s) to be addressed: A. Psychological symptoms (increased
depression, anxiety, and distress) will account for significant amount of variance in
predicting work-related cognitive limitations.

B. Somatic symptoms (fatigue, pain, and sleep disturbance) will account for significant
amount of variance in predicting work-related cognitive limitations.

C.Self-reported cognitive complaint will be positively correlated with work-related
cognitive limitation in both groups.

CI. After controlling for psychological and somatic factors, objective cognitive functioning
will emerge as a significant predictor of cognitive difficulty at work.

CII. After controlling for psychological and somatic factors, employed breast cancer
survivors will present with more work-related cognitive limitation in comparison to the
control group.

D. Marital status, race/ethnicity, age, education, and socioeconomic status will act as
moderators between psychological, somatic, and cognitive sequelae and work-related cognitive
limitation.

E. Medical variables, prior treatment, and work history will potentially act as covariates.

F. Level of mindfulness of attention and awareness will potentially act as a moderator in
level of cognitive performance at work place between both groups.

II. METHOD AND MATERIALS

1. Participants

1. Number, age, and type of participants The breast cancer survivors group will
include women between the ages of 18 to 69 who have had received a stage I-III
diagnosis of breast cancer in the past and completed primary treatment and
finished with treatment for at least 6 months. The healthy control group will
include women between the ages of 18-69 who are healthy with no diagnosis of
cancer. The participants in both groups will be employed working part-time or
full-time at the time of assessment. Participants working between 1 to 34 hours a
week will be considered part-time employees. The demographic sheet and
questionnaires are printed in English, so participants must speak English to
participate in the study. Because this is an Internet study, individuals will be
required to have access to a computer and the Internet. The number of
participants will be determined by the result of recruitment efforts from a
variety of sources, including online and in-person advertisement. The expectation
is for over 200 participants, 100+ for each group at minimum.

2. Procedure for selecting participants The investigator will contact agencies that
help researchers to recruit participants by email and/or phone to ask for their
permission to post/handout flyers as means of recruiting. The agencies will be
provided with sample flyer and explanation of how participants' consent will be
obtained and confidentiality protected. In addition, a description of the
intended use of the data will be provided. The investigator will also post flyer
and leaflets online and on hospital and universities campuses.

Individual interested in participating in the study will have an access to the
website indicated on the flyers. Participants will need to review the online
consent form and agree to the conditions, before being able to proceed to complete
the surveys. Participants will provide their informed consent by clicking on the
"Yes, I agree" button. The entire survey should take about 40-45 minutes to
complete.

3. Rationale for employing the type of participants selected for the study The
rationale for using these particular participants is because the study is about
the relationship between cancer-related symptoms and work-related cognitive
functioning among working female breast cancer survivors. In addition, a healthy
control group is needed for an effective and a qualitative study. By recruiting
from a variety of places, the sample will be more generalizable.

4. Are participants expected to benefit from the participation in the study? If so,
how? There are no expected benefits. However, potentially a participant might (a)
gain a better understanding of her experiences regarding her health (i.e. post
cancer health or general health), (b) gain a clearer idea about her psychological,
somatic, and cognitive conditions. In addition, it is the investigators hope that
through participation, researchers will learn more about the relationship between
biopsychosocial functioning and work-related cognitive limitation.

5. Are any risks to the participants from participation in the study? If so, what are
they? The foreseeable risks or discomfort are minimal, but could include emotional
discomfort about the content of the questionnaires and some distress as
participants are reminded of negative experiences. Referrals are provided at the
beginning of survey under the ALTERNATIVE section and at the end of the survey for
individual who may experience distress as a result of participating in the study.

6. Will participants be identified with the data? No identifying information will be
linked to participants' responses. Individuals' name and email address will be
inquired in order to access the Log in information to complete the Brain
Performance Test on Lumosity.com. This information will be stored on a
password-protected file and will not be linked to the survey responses.

2. Setting - Specify where your research will be conducted and, if appropriate, include a
signed letter of consent from the individual who approved research at this site.

Data collection will take place via the worldwide webs. Specifically, Qualtrics.com and
Lumosity.com will be utilized as a tool to collect participants' responses and
implement cognitive testing. Such a setup provides the participants with an
opportunity to participate in the study privately, at a time that is convenient for
them, and in a setting that is most comfortable for them.

3. Materials - Describe any test materials to be used, such as psychological, educational,
or evaluative tests. Please include copies of the above materials with the protocol,
and/or provide representative examples of computer stimulus materials.

Data collection will occur via a worldwide web.

Demographic Questionnaire (Developed by principle Investigator) The demographic sheet
includes general information such as age, gender, ethnicity, marital status, and level
of education.

Medical and Treatment History Questionnaire (Developed by principle Investigator) The
medical and treatment history questionnaire are questions pertaining to Breast Cancer
such as stage of diagnosis, length of time since diagnosis, Treatment length and
treatment status are also included. Lastly, several questions will address
participants' medical and family history.

Center of Epidemiological Studies of Depression (CES-D) The CES-D is a self-report
measure that measures depressive symptomology. The CES-D consists of 20 items, four of
which are worded in the positive direction to avoid a response set. Participants are
asked to choose on a 4-point Liker-scale (0 = Rarely or none of the time, 1= some or a
little of the time, 2=Occasionally or a moderate amount of time, and 3=Most or all of
the time) how frequently in the previous week they had experience the stated feeling or
symptoms. The total possible scores ranges from 0 to 60, with higher scores meaning
higher distress. Scores of 16 or higher will suggest an elevated level of depression.
The CES-D has an internal consistency of 0.85 in the general population and 0.90 in the
patient sample, indicating the measures reliability. In addition, the construct
validity of the scale presents four factors including depressive affect, somatic
symptoms, interpersonal relationships, and positive affect.

Generalized Anxiety Disorder - 7 (GAD-7) The GAD-7 is a 7 item self-report scale
assessing the extend of generalized anxiety in the general population. It assess the
frequency of times over the past two weeks that participants may have experienced the
seven symptoms central to general anxiety disorder. Responses ranges from 0) not at
all, 1) sometimes, 2) often, and 3) nearly every day. The numbers adds up for a
possible scores ranging from 0 to 21, with higher scores indicating higher levels of
generalized anxiety. The scores greater than 5, but less than 10 indicates mild
anxiety, with scores 10 or greater and less than 15 indicating anxiety. Scores 15 or
greater are indicative of severe anxiety symptoms. This measure has show good internal
consistency (alpha coefficient of 0.89)

Brief Pain Inventory -Short Form (BPI-SF) The BPI-SF is a 9-item self-report
questionnaires assessing pain severity and pain interference with daily functioning.
It assesses pain based on four pain severity items: 1) worst; 2) least; 3) average; and
4) now; and seven pain interference items including: 1) general activity; 2) walking;
3) work; 4) mood; 5) enjoyment of life; 6) relations with others; and 7) sleep. The
BFI-SF has been found to be a valid and reliable measure for assessing pain from cancer
with a cronbach alpha reliability of 0.77 to 0.91.

Brief Fatigue Inventory (BFI) The BFI is a 9-item self-report questionnaire with items
measured on 0-10 numeric rating scale assessing fatigue severity and fatigue
interference with daily functioning in clinical and research settings. It assesses
fatigue based on 3 items rating severity of their fatigue as "worst", "usual", and
"now" during waking hours, with 0 being "no fatigue" and 10 being "fatigue as bad as
you can imagine." In addition, six items assess the amount of fatigue that has
interfered with different aspects of the participants' life during the past week. The
interference items are measures on a 0 to 10 scale, with 0 being "does not interfere"
and 10 being "completely interferes." The BFI is found to be an internally reliable
measure best for interpreting the severity of fatigue and a reliable instrument used
for fatigue assessment among cancer patients.

Insomnia Severity Index (ISI) The ISI is a 7-item self-report questionnaire that
measures: 1) the severity of sleep-onset (initial); 2) sleep maintenance (middle); 3)
early morning awakening (terminal) problem; 4) satisfaction with current sleep pattern;
5) interference with daily functioning; 6) noticeability of the sleep problem; and 7)
degree of distress or concern caused by the sleep problem. Each item is rated on a
Likert scale ranging from 0 (not at all) to 4 (extremely). The ISI total score is
obtained by adding the scores of the 7 items (range 0-28). The ISI internal
consistency is high (r=0.78). Any score below eight is considered not clinically
significant insomnia.

Mindfulness Attention Awareness Scale (MAAS) The MAAS is a 15-item scale designed to
assess a core characteristic of mindfulness by measuring the awareness of present
moment (i.e. what is occurring, and what is taking place). This measure has shown
"excellent psychometric properties". The MAAS's internal consistency levels (Cronbach's
alphas) ranges from .80 to .90. In addition, this measure has shown high test-retest
reliability, discrimination and convergent validity, known-group validity, and
criterion validity.

Multifactorial Memory Questionnaire (MMQ) The MMQ is a self-report measure that
assesses three dimension of memory, including MMQ-Contentment, MMQ- Ability, memory,
and MMQ-Strategy. The MMQ-Contentment consists of 18 items, which each item is rated
on 5-point scale (i.e., "strongly agree", "agree", "undecided", "disagree", and
"strongly disagree"). The MMQ-Ability consists of 20 items, which each item is rated
on 5-point scale (i.e., "all the time", "often", "sometimes", "rarely", and "never").
The MMQ-Strategy consists of 14 items, which each item is rated on a 5-poin scale
(i.e., "never", "rarely", "sometimes", "often", and "all the time"). The MMQ is found
to have a high reliability for each dimension measured (MMQ-Contentment = 0.93;
MMQ-Ability = 0.86, and MMQ-Strategy= 0.88). This measure was reported to have
"excellent" content, construct and factorial validity and a reliable relevance(Troyer &
Rich, 2002) to be used in clinical applications.

Cognitive Symptom Checklist - Work 21 Item (CSC-W21) The CSC-W21 is a 21-item
self-report questionnaire that assesses work-related cognitive limitation among breast
cancer survivors. The measure uses dichotomous response scale of yes or no. The
higher scores on CSC-W21 are associated with greater work-related cognitive limitation.
The CSC-W21 has three factor models of: working memory, executive function, and task
completion subscales with a high demonstrated internal reliability (α =. 88). The
CSC-W21 have found to be valid and highly correlated with other subjective cognitive
measures such as Functional Assessment of Cancer Therapy-Cognition, Version 2
(FACT-COG) and CSC-W59 (CSC-W21 is a factor analysis of the CSC-W59).

Lumosity Brain Performance Test (BPT) The BPT is an assessment battery designed by
Lumos Labs. This measure is developed by the Lumosity Lab research and development team
and is based on validated and liable cognitive batteries including: Trail-making,
Memory Span assessments, Grammatical reasoning, and Stop signal task. The assessment
has raw scores and scaled scores in which are translated into an age-normed scaled
scores. These scores are interpreted based on a particular BPT calculation through the
site.

4. Procedures -

1. Describe what participants will be required to do, step by step.

2. State where, when, and by whom the research will be conducted.

3. Time Individuals will be welcomed to the study and introduced to the nature and
purpose of the study. They will then need to review and consent to the study
prior to being able to proceed to the questionnaires. If the individuals choose
to proceed with the study, they will then fill out the demographic, and medical
questionnaires as well as the six other questionnaires. Participants will have an
option of exiting the survey at any point by clicking on the "Exit" link available
at the top of each page. If a person drops out of the study, their responses will
not be included in the data. Participants will complete the survey a single time.
The entire study should take no more than 40-45 minutes to complete.

4. Confidentiality - Describe mechanisms for maintaining confidentiality

Participation in research may involve a loss of privacy, but information will be
handled as confidentially as possible. To participate in the study, the
individuals need to access the website and remain anonymous. The demographic
sheet and questionnaires do not ask the participants to identify any information
such as their name or home address, thus protecting the participant's privacy.

Individuals' name and email address will be inquired separate from their survey
response. This information is needed so that the individuals could be provided
with a Log In ID to access the Brain Performance Test at Lumosity.com. No
identifying information will be required on Lumosity webpage other than the Log In
information, which will be provided on the Primary Investigators Qualtrics page.
Lumos Lab will have no access to the survey responses or the individual's
identification. They will only gather the data from the battery anonymously.

No personal information shall be disclosed to anyone without the individual's
permission or unless required by law (i.e., court-ordered release of information,
duty to protect against imminent danger to self or others and suspicion of child,
dependent, or elder abuse). Information obtained in this research project may be
published in journals or presented at meetings but no identifying information
shall be revealed.

5. Consent Process and Documentation

Participating in the study is the individuals' choice, and individuals will provide their
informed consent to become part of the study after being receiving extensive information
about the purpose of the study by pressing the "Yes" button. A memo will be written on the
survey suggesting that the participants print out a copy of the consent form for their
records. Throughout the study, the option to end the study will be available, as consent in
a process rather than a one-time agreement.

Individuals 18 to 69 years of age will be invited to participate. There is no deception
involved in the study and the consent form outlines the way data will be handled. No
special population, such as children or inmates, will be included in the study. Therefore,
no assent forms are necessary.

The study will take place in English. All the measures are available in English, thus no
translation of the measures was necessary.

Inclusion Criteria for breast cancer survivor group:

- Female

- Between the age of 18 to 69 years old

- Working part-time or full-time at the time of the assessment

- English-speaking

- Have Internet and computer access

- Have completed primary treatment and finished with treatment for at last 6 months
(hormonal blockade therapy is permitted)

- Have received a stage I-III diagnosis of cancer

Inclusion Criteria for control group:

- Female

- Between the age of 18 to 69 years old

- Working part-time or full-time at the time of the assessment

- English-speaking

- Have Internet and computer access

- Have no cancer diagnosis

Exclusion Criteria:

- Diagnosis of dementia, history of brain injury and adult attention deficit
hyperactivity (ADHD), epilepsy, current drug or alcohol abuse